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ABSTRACT 
This study aimed to investigate the prevalence of and factors associated with non-
adherence to medication amongst a sample of breast cancer patients. 131 women with 
stable disease were interviewed and completed standardised psychological measures. 
55% of women reported non-adherence to medication frequently or occasionally, with 
younger women and those who disliked taking their medication being significantly 
less adherent (P =0.015, P =0.001). Women who deliberately omitted taking their 
tablets occasionally or frequently had significantly lower scores, indicative of a 
weaker influence, on ‘internal’ and ‘powerful others’ dimensions of health locus of 
control (P =0.032, P =0.009). Despite a life-threatening diagnosis, patients may not 
adhere to medication representing a potential missed opportunity for health gain and 
waste of resources. Furthermore, interpretation of clinical trial data may be 
misleading without adherence information. More research is needed to identify those 
at risk for non-adherence. If other routes of administration are available these options 
should be discussed with patients to maximise efficacy of therapy.  
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INTRODUCTION 
The pharmaceutical industry invests large sums of money into the development of 
oral rather than injectable drugs. As more are developed, patient adherence to 
regimens becomes an increasingly important issue. Reported rates of adherence to 
oral drugs vary between 19-100% [1]. Non-adherence to treatment represents not only 
a missed opportunity for health gain and waste of resources [2] but also renders the 
interpretation of clinical trial data as potentially unrealistic in the absence of 
adherence data [1]. 
 
Definition and Measurement of adherence 
The increase in patient autonomy has led to the term ‘adherence’ replacing the more 
authority-laden term ‘compliance’ in the literature. The most commonly cited 
definition of adherence is ‘the extent to which a person’s behaviour coincides with 
medical or health advice’ [3]. However, it should be noted that a distinction is not 
always made in the literature regarding the conceptual difference between intentional 
non-adherence when a patient makes a specific decision not to take the prescribed 
medication and non-intentional non-adherence as a result of forgetting or 
misunderstanding instructions about the drug schedule.  
 
A number of different approaches have been taken when assessing adherence; these 
include determining whether or not medication has been taken in the correct dose, at 
the correct time or by establishing the amount of the prescribed dose consumed. There 
are also different methods of measurement such as drug levels in biologic fluids, 
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patient observation, electronic monitoring or patient self-report in the form of 
interview, questionnaire or diary. These differing means of assessment could 
contribute to the variable rates of adherence reported in the literature. Nevertheless, 
Powles and colleagues [4] reported a 96% agreement between objective blood-testing 
and patient self-report of adherence amongst patients taking tamoxifen, who were 
participating in the IBIS chemoprevention trial. 
 
Factors related to non-adherence 
Adherence to medication is not necessarily related to sociodemographic factors such 
as age, sex, level of education or race [5] but rather that patients are less likely to 
adhere to those therapies that have adverse side-effects [6] are complex and/or last 
longer [5]. Evidence regarding all these issues has been mixed. Elwyn and colleagues 
[6] suggest that intentional non-adherence to medication is the result of three factors: 
1) a lack of information about the advantages and disadvantages of the treatment; 2) 
when the benefits of treatment are not obviously apparent and; 3) the psychological 
adaptation required to see oneself as in need of treatment. Patients often lack 
sufficient information regarding the pros and cons of treatment. Clinician-recorded 
side-effects tend to emphasize serious, life-threatening adverse events rather than 
patient-reported issues affecting quality of life [7]. This means that decisions about 
embarking on treatment might be based on a faulty appraisal of true patient burden.  
Adherence is less likely where the benefits of drugs are not immediately obvious, this 
is particularly salient to women on a five-year hormone regimen which does not offer 
a guarantee of recurrence-free survival but does produce side-effects.  The 
psychological adjustment in self–perception for someone who has to take medication 
may hinder adherence and is particularly relevant for women with breast cancer on 
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hormone regimens for several years. If they are disease-free post surgery and 
chemotherapy, they may not want to continue seeing themselves as being ill. Tablet 
taking is a constant reminder. 
 
Most of the literature concerning patient adherence to medication has focussed on 
areas such as HIV, hypertension and psychiatric illness; patients’ adherence to 
medication in illnesses such as breast cancer has received less attention. However 
where the issue has been investigated, rates of non-adherence to regimens of 
tamoxifen therapy have been reported as being between 15-50% with follow-up of 
between 2-5 years [8-11]. 
 
In a study investigating discontinuation of tamoxifen use, Fink and colleagues [8] 
report that 88 out of the 516 patients with oestrogen receptor-positive breast cancer 
had stopped taking tamoxifen by two years. Factors such as age and side-effects were 
not associated with discontinuation, however, similar to previous findings regarding 
the role of patients’ beliefs [2, 12], negative beliefs regarding the value of the 
medication and positive-node status were associated with discontinuation. This 
finding highlights the need for effective communication with patients about mode of 
action and benefits of medication if optimal adherence is to be achieved. This can be 
difficult in an adjuvant setting when patients recognise that they may not even need or 
benefit from further treatment. Clinicians sometimes offer reassurances that further 
drug treatment is merely given as an extra insurance policy but this might limit 
motivation to take drugs regularly even further. 
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Other studies investigating adherence to tamoxifen have reported associations with 
side-effects [10]. Demissie and colleagues report that patients who experience side-
effects were significantly more likely to stop taking tamoxifen [10]. Elsewhere, 
adherence has been associated with age, with younger women or women who had 
undergone mastectomy rather than breast-conserving surgery being less likely to 
adhere [11]. 
 
The impact that patients’ personal beliefs about their illness has on adherence has 
received limited attention. In one study looking specifically at intentional non-
adherence, Iihara and colleagues [12] suggest that patients with chronic illness facing 
long-term therapies make decisions about treatments based on their own beliefs. They 
found that patients who attached a greater value on knowing the side-effects were 
significantly more likely to intentionally non-adhere to medication than those who did 
not place a value on this knowledge. Other factors reported to be associated with 
intentional non-adherence were poor level of comprehension regarding general 
medication and age, with patients who were aged between 40 and 49 being less likely 
to adhere to medication than both younger and older patients.  
 
Variations in adherence to treatment can be explained from the perspective of social 
cognition theoretical models [2]. Individuals develop beliefs which influence the 
interpretation of information which ultimately guide behaviour, thus patients may 
conduct a cost benefit analysis weighing the necessity of taking medication against 
concerns regarding potential adverse effects. In a sample of 83 oncology patients, the 
difference score between the perceived necessity and concerns was the strongest 
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predictor of adherence to medication over and above clinical or sociodemographic 
factors [2].  
 
 
As part of a wider study investigating breast cancer patients’ preferences for different 
routes of administration of hormone therapy [13], we  also examined the adherence of 
those receiving medication. We recorded self-reported intentional and non-intentional 
non-adherence and the different personality and demographic factors associated with 
this. Locus of control has been discussed previously in the literature in relation to 
adherence. Partridge and colleagues [14] suggest that the degree of control an 
individual feels they have over their illness may influence adherence to medication. 
They hypothesise that an individual who believes they have greater influence over 
their situation would be more likely to adhere to medication whereas individuals with 
a fatalistic view of their situation would be less adherent. The present study will 
therefore also investigate the role of locus of control in adherence and would 
anticipate that our findings support these hypotheses. 
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PATIENTS AND METHODS 
Participants 
Women attending routine follow-up appointments were identified by clinic staff and 
invited to join a study about preferences for different routes of administration of 
breast cancer drugs. Inclusion criteria were being a minimum of two years post-
diagnosis, with stable disease, ability to speak English and provide informed consent. 
Women were recruited from clinics at Christie and Withington Hospitals, Manchester; 
Velindre Hospital, Cardiff; Charing Cross Hospital, London; Worthing Hospital, 
Worthing and Royal Sussex County Hospital, Brighton providing a wide geographical 
spread. A total of 208 out of 270 women, when approached in clinic by a research 
psychologist agreed to be interviewed at a later date in their own homes.  The 
interview took approximately one hour to complete. One hundred and thirty one 
patients were currently receiving medication and are included in this study about 
adherence. 
 
Measures 
A semi-structured interview schedule was devised to elicit patients’ preferences 
between two routes of administration of hormone therapy; a daily tablet or a monthly 
injection and included questions regarding relevant factors such as 
sociodemographics, information regarding medical regimens, treatment experience 
and adherence. Patients were asked about these experiences of treatment and asked to 
indicate whether there were any aspects of their current regimen that they disliked, for 
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example side-effects of hormone therapy such as hot flushes or night sweats. Non-
intentional non-adherence was assessed via the question “how often do you forget to 
take your tablets?” and intentional non-adherence with “how often do you choose not 
to take your tablets?” For both questions patients had the response options of ‘never’, 
‘occasionally’, ‘sometimes’, ‘quite often’ and ‘very often’. Responses to questions 
addressing the issues of intentional and non-intentional adherence were recoded to 
form two dichotomised dependent variables, ‘adherence’ and ‘intention’. The 
adherence variable comprised two categories; adherers who said they neither forgot 
nor chose not to take their medication (i.e. responded ‘never’ to both questions) and 
non-adherers who said they either occasionally, sometimes, quite often or very often 
either forgot to, choose not to take their medication or both. The intention variable, 
created from the non-adherers sub-sample of the adherence variable, comprised two 
categories; intentional non-adherers who reported choosing not to take their 
medication and non-intentional non-adherers who reported forgetting to take their 
medication. All researchers were trained in interviewing techniques and each 
interview was tape recorded to permit independent checking of data. 
 
Patients were also asked to complete the Multidimensional Health Locus of Control 
Scale (MHLOC) [15]. The MHLOC is an 18-item scale assessing respondents’ 
feelings of self-control over their illness (internal) and the extent to which they feel 
‘powerful others’ and ‘chance’ factors influence their general health. The scale 
produces three scores (derived from six items each). The scale is scored on a 6 point 
scale anchored at 1 = ‘strongly disagree’ to 6 = ‘strongly agree.’ A higher score is 
indicative of a stronger influence of the dimension in health behaviours.   
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Statistical analysis 
All data were analysed using SPSS v11.5. The two dependent variables, ‘adherence’ 
and ‘intention’ were then subject to chi-square analysis to identify any association 
with relevant factors (age, aspects of medication disliked, number of tablets currently 
taken, MHLOC) which were then entered into a logistic regression analysis.   
 
The study had full MREC and LREC approvals. 
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RESULTS  
The mean age of the patient population was 59.4 (SD ±11.53). 62.6% were married 
and 52.7% had received at least secondary level education. Sociodemograpic and 
treatment information is detailed in Table 1. Rates of adherence and intention to 
adhere are detailed in Table 2. Tamoxifen was the most commonly prescribed drug in 
the sample. Of the 72 prescribed tamoxifen, 33 reported adhering to their medication 
and 39 reported instances of non-adherence. Of the 39 who reported non-adherence, 6 
reported instances of intentional non-adherence and 33 reported instances of non-
intentional non-adherence. The second most common drug prescribed to the sample 
was anastrozole. Of the 36 women who reported taking it, 14 reported adhering to 
their medication and 22 reported not adhering to their medication. Of the 22 who 
reported non-adherence, 4 reported being intentionally non-adherent and 18 reported 
being non-intentionally non-adherent. 
 
Adherence 
An independent samples t-test revealed that age was associated with adherence to 
medication as younger women were significantly more likely to non-adhere (t  
=2.483, df  =105.377, P =0.015, 95%CI: 1.002 to 8.947).  
Chi-square analysis revealed a significant association (P =0.001) between whether or 
not the women disliked any aspects of their current medication (e.g. side-effects, 
difficulties swallowing tablets and inconvenience) and adherence; those who disliked 
aspects of their current medication were significantly more likely to non-adhere.  
 
The number of tablets taken for breast cancer and co-morbidities was not found to be 
significantly associated with adherence. 
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Age and aspects of treatment disliked were then entered into a logistic regression 
analysis using a forward selection procedure which revealed that dislike of aspects of 
their current treatment was significantly predictive of adherence at P <0.001  
(β =-1.415, S.E. =0.421, Exp(β) =0.243).  
 
Intention 
An independent samples t-test revealed that patients who reported forgetting to take 
their medication had significantly higher scores on the ‘internal’ (t =2.195, df = 68,  P 
=0.032, 95%CI: 0.315 to 6.599) representing an effect size of r =0.26, and ‘powerful 
others’ (t =2.710, df =67, P =0.009, 95%CI: 1.38 to 9.093) representing an effect size 
of r =0.31, subscales of the MHLOC than those who reported choosing to not take 
their medication. Means and standard deviations for all MHLOC scores are detailed in 
Table 3. Due to the sample sizes, caution must be taken when drawing inference from 
these findings. 
The ‘internal’ and ‘powerful others’ variables were then entered into a logistic 
regression analysis using a forward selection procedure which revealed that 
participant scores on the ‘powerful others’ subscale was significantly predictive of 
intention at P <0.013 (β = -0.166, S.E. = 0.067, Exp(β) = 0.847).  
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DISCUSSION 
Non-adherence to medication amongst patients treated for breast cancer clearly exists 
and there is some evidence to suggest that differences exist between those who forget 
and those who choose not to adhere to medication.  
 
Of the 131 patients who were currently receiving medication for their breast cancer, 
55% reported that they did not adhere to medication. The majority of these non-
adherers (83.3%) reported this as unintentional because they forgot to take their 
medication, but approximately 1 in 6 (16.7%) reported intentionally choosing not to 
take their medication.  
 
Adherence was associated with age as younger women were significantly more likely 
to report not taking their medication. Some clinicians may find this result surprising, 
as intuitively it would be expected that older women would be more likely to forget. 
In addition, patient reports of whether they disliked some aspect of taking their 
medication in particular unpleasant side-effects such as hot flushes, were significantly 
predictive of whether they adhered to their medication. Similar findings have been 
reported amongst women taking tamoxifen in the adjuvant setting with almost half of 
the non-adherent sample reporting side-effects as the reason for non-adherence [16] 
 
There was evidence to suggest that intention regarding non-adherence was related to 
health locus of control. Patients who reported deliberately missing their medication 
viewed themselves according to MHLOC as having significantly less influence over 
their own health than patients who reported forgetting to take their medication. 
Additionally, patients who reported forgetting to take their medication also had a 
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significantly stronger belief that powerful others (such as health professionals, family, 
friends) could help improve their health than did patients who intentionally chose not 
to take their medication. This factor was significantly predictive of whether patients 
choose or forgot to take their medication. We anticipated that individuals with a 
higher internal locus of control would be more likely to adhere to medication. This 
was not supported with regards to whether individuals did or did not adhere to 
medication, but did have a role to play with regards intention. There was no support 
for the hypothesis that individuals scoring highly on the chance dimension of the 
MHLOC scale were less likely to adhere. It would appear that MHLOC is useful in 
explaining the degree to which non-adherence to medication is intentional should be 
taken into account in future research.      
 
One issue worthy of comment concerns the veracity of responses given by patients. It 
is possible that they found it easier to report ‘forgetting’ to take tablets than the less 
socially desirable admission that they chose not to take them. Younger women in 
particular were more likely than older women to forget their tablets. 
 
Neither degree of interference in daily life from tablet taking or problems attending 
clinic were associated with adherence or intention. 
 
Future research might investigate the reasons why individuals intentionally and non-
intentionally avoid taking their medication. In this particular population of women on 
hormone therapy, the reasons for non-adherence may be both physical and 
psychological. The advantages of not taking medication are that women benefit from 
a cessation in adverse side-effects such as hot flushes whilst avoiding the constant 
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reminder of their illness. It is also conceivable that women may not feel the need to 
take medication as prescribed if they are asymptomatic. In addition, these effects are 
felt immediately whereas any negative affects such as disease recurrence may not be 
felt for a long time.  
 
Given the finding of Horne and Weinman [2] that patients’ analysis of the costs and 
benefits was the strongest predictor of adherence in oncology patients; further 
research should also investigate degree to which patients understand the mode of 
action and benefits of therapies received. 
 
The findings presented here, particularly the associations between adherence and 
health locus of control reflect the role of health beliefs and expectations in guiding 
behaviour. This has been discussed previously in the literature [14] and a more in 
depth investigation of the role of underlying psychological mechanisms would 
enlighten and benefit future research. 
 
Even when faced with a potentially life-threatening illness such as breast cancer, it 
cannot be assumed that patients will adhere to medication. There is some evidence 
that adherence is influenced by factors such as age and behavioural characteristics but 
the whole area is quite complex. Clearly communication about the advantages and 
disadvantages of respective treatments may improve adherence especially if women 
are encouraged to report side-effects and are given effective ameliorative treatments 
for these. Also those at most risk of non-adherence could perhaps be offered drugs 
with alternative routes of administration. Finally, more research is needed into the 
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development of interventions to improve adherence of women embarking on long-
term oral hormone regimens. 
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Table 1.  Sociodemographic and breast cancer medication   
Age 59.40 (SD 11.53) Range 56 (32-88) 
 
 
Marital status Ns (%) 
 
Married  
 
82 
 
(62.6%) 
 Single 13 (9.9%) 
 Living with partner 1 (0.8%) 
 Separated 4 (3.1%) 
 Divorced 14 (10.7%) 
 Widowed 17 (13.0%) 
 
 
Education Ns (%) 
 
Secondary 
 
69 
 
(52.7%) 
 Further 25 (19.1%) 
 Higher 35 (26.7%) 
 Missing 
 
2 (1.5%) 
 
DRUG 
 
BRAND NAME 
 
Ns (% total sample) 
Hormone/antibody: 
tamoxifen Noladex D/Soltamox/Tamofen 72 (34.6%) 
anastrozole Arimidex 36  (17.3%) 
exemestane Aromasin 9 (4.3%) 
letrozole Femara 6 (2.9%) 
zoledronic acid Zometa 4 (1.9%) 
goserelin Zoladex 3 (1.4%) 
megestrol Megace 3 (1.4%) 
trastuzumab Herceptin 2 (1%) 
fulvestrant Faslodex 1 (0.5%) 
leuprorelin Prostap 1 (0.5%) 
Total taking hormone 
 
137  (65.9%) 
 
Chemo: 
capecitabine Xeloda 1 (0.5%) 
paclitaxel Taxol 1 (0.5%) 
vinorelbine Navelbine 1 (0.5%) 
Not named Not named 1 (0.5%) 
Total in sample presently receiving chemotherapy 4 (1.9%) 
 
8 patients were taking 2 drugs and 1 patient was taking 3 drugs for  
their breast cancer. 
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Table 2. Adherence and Intention 
   
 
n =131 Adherence (n =2 missing) 
 
Adherent Non adherent 
57    (43.5%) 72    (55%) 
 
n =72 Intention 
 
Intentional non adherence  Non intentional non 
adherence  
12    (16.7%) 60    (83.3%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Patient characteristics and MHLOC scores * adherence and intention; mean scores (SD) 
 
Adherence 
 
Intention   
 
 Adherers (SD) Non-adherers (SD) 
 
Intentional (SD) Non-intentional  (SD) 
 
Mean (SD) 
Age 62.54    (12.34) 57.57    (9.826)* 58.67    (5.614) 57.35   (10.489)    59.40    (11.534) 
 
Internal 
 
 
23.98    (5.366) 
 
23.11    (5.101) 
 
20.25    (5.956) 
 
23.71    (4.750)* 
 
23.54     (5.19) 
Powerful Others 
 
20.23    (5.812) 18.49    (6.361) 14.17    (5.458) 19.40    (6.199)** 19.26    (6.136) 
Chance 19.21    (5.123) 17.54    (5.560) 15.50    (4.503) 17.97    (5.697) 18.33    (5.382) 
 
 
* Significant at P <0.05 
 
** Significant at P <0.01
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